Side-effects in women treated with adjuvant endocrine therapy for breast cancer
Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. A...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977625000359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343573154070528 |
|---|---|
| author | L.M. Rademaker R. Gal A.M. May M.C.T. Batenburg F. van der Leij R.M. Bijlsma H.M. Verkooijen A. Doeksen M.F. Ernst D.J. Evers C.C. van der Pol E.M. Monninkhof |
| author_facet | L.M. Rademaker R. Gal A.M. May M.C.T. Batenburg F. van der Leij R.M. Bijlsma H.M. Verkooijen A. Doeksen M.F. Ernst D.J. Evers C.C. van der Pol E.M. Monninkhof |
| author_sort | L.M. Rademaker |
| collection | DOAJ |
| description | Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016). |
| format | Article |
| id | doaj-art-2eb9d28e90f24c5e935c12badfa2ba65 |
| institution | Kabale University |
| issn | 1532-3080 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj-art-2eb9d28e90f24c5e935c12badfa2ba652025-08-20T03:42:56ZengElsevierBreast1532-30802025-04-018010441610.1016/j.breast.2025.104416Side-effects in women treated with adjuvant endocrine therapy for breast cancerL.M. Rademaker0R. Gal1A.M. May2M.C.T. Batenburg3F. van der Leij4R.M. Bijlsma5H.M. Verkooijen6A. Doeksen7M.F. Ernst8D.J. Evers9C.C. van der Pol10E.M. Monninkhof11Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the NetherlandsDivision of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the NetherlandsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, the NetherlandsDepartment of Medical Oncology, University Medical Centre Utrecht, Cancer Centre, Utrecht, the NetherlandsDivision of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the NetherlandsDepartment of Surgery, St. Antonius Hospital, Nieuwegein, the NetherlandsDepartment of Surgery, Alexander Monro Clinics, Bilthoven, the NetherlandsDepartment of Surgery, Hospital Group Twente, Almelo, the NetherlandsDepartment of Surgery, Alrijne Hospital, Leiderdorp, the NetherlandsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Corresponding author.Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).http://www.sciencedirect.com/science/article/pii/S0960977625000359Adjuvant therapyEndocrine therapyER positiveSide-effectsDiscontinuation of therapy |
| spellingShingle | L.M. Rademaker R. Gal A.M. May M.C.T. Batenburg F. van der Leij R.M. Bijlsma H.M. Verkooijen A. Doeksen M.F. Ernst D.J. Evers C.C. van der Pol E.M. Monninkhof Side-effects in women treated with adjuvant endocrine therapy for breast cancer Breast Adjuvant therapy Endocrine therapy ER positive Side-effects Discontinuation of therapy |
| title | Side-effects in women treated with adjuvant endocrine therapy for breast cancer |
| title_full | Side-effects in women treated with adjuvant endocrine therapy for breast cancer |
| title_fullStr | Side-effects in women treated with adjuvant endocrine therapy for breast cancer |
| title_full_unstemmed | Side-effects in women treated with adjuvant endocrine therapy for breast cancer |
| title_short | Side-effects in women treated with adjuvant endocrine therapy for breast cancer |
| title_sort | side effects in women treated with adjuvant endocrine therapy for breast cancer |
| topic | Adjuvant therapy Endocrine therapy ER positive Side-effects Discontinuation of therapy |
| url | http://www.sciencedirect.com/science/article/pii/S0960977625000359 |
| work_keys_str_mv | AT lmrademaker sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT rgal sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT ammay sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT mctbatenburg sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT fvanderleij sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT rmbijlsma sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT hmverkooijen sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT adoeksen sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT mfernst sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT djevers sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT ccvanderpol sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer AT emmonninkhof sideeffectsinwomentreatedwithadjuvantendocrinetherapyforbreastcancer |